Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 BASi Launches CRO Rebrand | Contract Pharma
Breaking News

BASi Launches CRO Rebrand

Inotiv is the new name of its contract research services business.

Bioanalytical Systems, Inc. (BASi), has launched its new contract research services brand, Inotiv. Inotiv represents the union of BASi’s Seventh Wave Laboratories and Smithers Avanza Toxicology Services in vivo toxicology, pharmacology, drug metabolism, bioanalysis, and pharmacokinetic (PK) solutions. The rebrand reflects the company’s increased scope of services and its resulting position as a top contract research organization (CRO) for drug discovery and development. 
 
The combined organization provides data and insights that drug developers need, while the legacy companies’ integrated, complementary resources and capabilities offer a comprehensive service portfolio for this space.
 
“Developers should expect more from their laboratory partners,” said Bob Leasure, president and chief executive officer. “We provide a full range of nonclinical and analytical services and adapt them seamlessly to each client’s goals. With the timely, focused insights they deserve, clients get the answers they need to advance confidently to their next milestones.”
 
The rebrand of the company’s contract research services business includes a new logo, philosophy, positioning, and website. Visit inotivco.com.
 
The company’s products business will continue to operate under the name BASi.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters